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Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterised by significant clinical heterogeneity and as
such reliable biomarkers are required to measure disease activity and assess treatment response. Recent advances in
our understanding of disease pathogenesis and the discovery of novel serum-based, electrophysiologic and imaging
biomarkers allow clinicians to make more informed decisions regarding individualised treatment regimes.
As a chronic immune-mediated process typified by relapse following withdrawal of immunomodulatory therapy, a
substantial proportion of patients with CIDP require long term treatment with intravenous immunoglobulin (IVIg), a
scarce and expensive donor-derived resource. The required duration and intensity of immunoglobulin treatment vary
widely between individuals, highlighting both the heterogeneous nature of the underlying disease process as well as
the variable pharmacologic properties of IVIg.
This review outlines the use of multimodal biomarkers in the longitudinal evaluation of nerve injury and how recent
developments have impacted our ability to predict both response to immunoglobulin administration and its withdrawal.
Keywords: Chronic inflammatory demyelinating polyneuropathy, Intravenous immunoglobulin, Biomarkers, Paranodal
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Background
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is the most common chronic immune-mediated
neuropathy worldwide, with an estimated prevalence of
2–7 per 100,000 people [1]. While therapeutic advances
have resulted in a reduction in morbidity, CIDP con-
tinues to be associated with considerable disability, with
almost three-quarters of patients not returning to their
previous level of function [2]. Although effective, trad-
itional corticosteroid regimes are implicated in a wide
variety of adverse effects and consequently a substantial
proportion of patients require long term treatment with
intravenous immunoglobulin (IVIg), a scarce donor-de-
rived resource both costly and inconvenient [3].
The current approach to diagnosis and treatment of
CIDP has several significant limitations. While foremost
amongst these is the lack of a safe, efficacious and
readily accessible therapy, the lack of effective disease
biomarkers has resulted in an inability to stratify patients
to individualised treatment regimes. While clinical re-
sponse to treatment can provide an indication of disease
activity, objective measures of assessing therapeutic
effect and predicting outcome are limited, and this has
many implications on assessing the required duration
and intensity of immunoglobulin therapy.
Diagnosis and clinical staging of CIDP
The initial diagnosis of CIDP is clinical, with patients
presenting with a characteristic pattern of weakness and
areflexia that evolves over a period of more than 2
months. Confirmation of diagnosis is made by demon-
strating evidence of peripheral nerve demyelination,
most commonly by electrophysiological testing with
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supportive findings on cerebrospinal fluid analysis and
rarely nerve biopsy.
In lieu of well-defined objective measures of disease
activity, a variety of scoring systems based on functional
status have been developed to quantify disease severity.
Commonly used scales include the Inflammatory Neur-
opathy Cause and Treatment (INCAT) overall disability
sum score which relies on self-reported impairment in
undertaking activities of daily living and the Medical
Research Council (MRC) Muscle Sum Score which relies
on examiner-based evaluation of strength in a variety of
muscles (See Table 1) [4–8].
While reflecting functional status is important, clinical
scores are imperfect approximations of disease activity
and their utility in guiding therapeutic decisions in a
complex heterogeneous condition like CIDP is clearly
limited. Despite consensus guidelines, rates of misdiag-
nosis in CIDP may exceed 40%, and an over-reliance on
self-reported treatment benefits may lead to inappropri-
ate utilisation of resources and subjecting patients to
unnecessary treatment risks [9].
Reliable biomarkers of disease activity are thus re-
quired to not only aid diagnosis, but also monitor longi-
tudinal disease activity and predict individual responses
to both immunoglobulin treatment or its withdrawal.
Biomarkers of disease activity
A heterogeneous disease process that affects patients to
different degrees of severity, various pathogenic mecha-
nisms have been suspected to drive peripheral nerve
demyelination in CIDP. While the presence of inflamma-
tory infiltrates on sural nerve biopsies implicate a cell-
mediated immune response, early animal-based studies
demonstrating that inoculation of sera from CIDP pa-
tients produced a demyelinating phenotype and the
proven efficacy of plasma exchange in treatment strongly
suggest that humoral autoimmunity underpins disease
pathogenesis [10, 11].
Serum based biomarkers of disease activity
Extensive attempts to identify antibodies against myelin
based protein peptides have been largely unrewarding
[12]. Studies examining other neuronal structures how-
ever, with particular scrutiny on proteins associated with
the nodal and paranodal junctions have yielded more
promising results. Indeed, while pathogenesis in CIDP
has traditionally been conceptualised as being purely
myelin based, it is becoming increasingly evident that
‘demyelination’ may be a more complex phenomenon
that also involves a disruption of nodal and paranodal
regions [13].
The discovery of paranodal antibodies to neurofascin
and contactin-1 isoforms have been described in a mi-
nority of patients with severe CIDP and the presence of
these antibodies appear to predict a phenotype charac-
terised by aggressive symptom onset, sensory ataxia and
poor response to IVIg [14, 15]. Identification of these
antibodies has provided the first direct evidence of
disease-specific biomarkers that provide a tantalising
step forwards into the realm of individualised treatment
regimes.
Anti-neurofascin 155 (anti-NF155) and anti-contactin
1 (anti-CNTN1) antibodies have been identified in
approximately 3–10% of patients with chronic infamma-
tory polyneuropathies [16–18]. Patients who tested posi-
tive to these paranodal antibodies responded favourably to
B-cell depleting therapies like rituximab over more trad-
itional therapeutic options like IVIg or plasmapheresis.
Although only small groups have been studied, a correl-
ation between antibody titre and disease activity has been
Table 1 Clinical scoring systems in Chronic Inflammatory Demyelinating Polyneuropathy
Clinical scoring system First published Range Examines Scored by








INCAT Overall Disability Sum score Merkies et al., 2002 [5] 0–12 Upper and lower limb functional questionnaire Patient
Adjusted INCAT Identical to INCAT disability score but changes in upper limb function from 0 (normal)
to 1 (minor symptoms) excluded.
INCAT sensory subscore Merkies et al., 2000 [8] 0–20 Sensory modalities in upper and lower limb areas and 2-point
discrimination at index finger
Examiner
Overall Neuropathy Limitations Scale Graham et al., 2006 [7] 0–12 Modified ODSS which also includes question regarding running
or climbing stairs
Patient
Rasch-built Overall Disability Scale Van Nes et al., 2011 [6] 0–24 Upper and lower limb functional questionnaire; score of 0–2 in
12 activities eg. washing, climbing stairs
Patient
Abbreviations: MRC Medical Research Council, INCAT Inflammatory Neuropathy Cause and Treatment, ONLS Overall Neuropathy Limitations Scale
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observed, with successful treatment characterised by a
concomitant reduction in antibody levels suggesting
these titres could also be used to monitor progress
over time [19].
Testing for different immunoglobulin classes of para-
nodal antibodies may be useful in evaluating patients
with a phenotype of aggressive, younger-onset inflamma-
tory neuropathy (even if this resembles a Guillain-Barré
Syndrome) particularly in the setting of either treatment
resistance or clinical relapse following an initial response
to IVIg therapy. While transient IgM responses to
neurofascin can be seen in patients with GBS, the pres-
ence of IgG4 antibodies appears to be extremely specific
for an eventual diagnosis of CIDP [17, 18]. It could be
hypothesized that presence of paranodal antibodies of
the IgM class may increase risk of progression to CIDP
(IgM class switching is mandatory for IgG4 antibody
formation) and this could be an indication for height-
ened vigilance even if initial presentation is atypical.
Despite the promise shown by these discoveries, the
identification of IgG4 paranodal antibodies in patients
with CIDP remains rare, and while early indications of a
specificity approaching 100% make them an invaluable
tool for assessing patients with suggestive clinical
presentations, more ubiquitous biomarkers are clearly
necessary for routine clinical use [17].
Serologic responses to therapy
Although the scarcity of detectable antibodies in CIDP
mean they are an impractical method of measuring
disease activity, the quantifiable serologic response to
immunoglobulin treatment has been proposed as an
alternative surrogate biomarker.
The mechanisms by which IVIg exerts a regulatory
effect on the dysimmune response in CIDP has not been
completely established, though in-vivo studies have
suggested it may neutralize pathogenic autoantibodies,
inhibit complement binding and possibly act directly on
the myelin sheath to enhance remyelination [20]. These
pharmacodynamic mechanisms are driven to different
degrees in affected patients, hence explaining individual
responses to treatment. More importantly, pharmacoki-
netic effects directly influencing serum immunoglobulin
levels after IVIg administration likely explain the
variability in individual responsiveness and the clinical
observation that patients experience a ‘wearing-off ’
effect at different time-points after treatment [21, 22].
There is mounting evidence to support an immuno-
globulin dose-response relationship in inflammatory
neuropathies, with higher serum levels after IVIg admin-
istration associated with a superior treatment response
[23, 24]. Certainly in acute inflammatory demyelinating
polyneuropathy, statistically significant associations be-
tween change in IgG levels after IVIg and various functional
endpoints such as muscle strength and being able to walk
unaided have been demonstrated. While the association
between change in immunoglobulin G level (ΔIgG) and
clinical outcome has not been as comprehensively evalu-
ated in CIDP, small group experimental data appears to
support a similar positive relationship [25].
Following the results of the Intravenous Immuno-
globulin CIDP Efficacy (ICE) trial which established IVIg
as an effective therapy for CIDP, the standard approach
to initiating treatment has been to commence with an
induction dose of 2 g/kg IVIg over 2–5 days. This rec-
ommendation however does not take into account
patient-specific pharmacokinetic responses, and adjust-
ing treatment dose based on immunoglobulin levels may
help guide more effective individualised treatment
regimes. A study of change in immunoglobulin G level
(ΔIgG) following treatment actually demonstated wide
variability between patients unrelated to weight or body
mass index [21]. As such, although current practice
bases total treatment dose on weight, many other factors
influence IVIg pharmacokinetics and it is likely that
other variables including fraction of dimeric IgG and frag-
ment crystallizable (Fc) receptor polymorphisms have a
direct influence on IVIg efficacy and metabolism [26].
Comprising pooled IgG derived from between 1000
and 15,000 different donors, IVIG preparations consist
of predominantly monomeric IgG with small percent-
ages (5–15%) of dimeric complexes. This is relevant as
increased dimeric fractions have been reported to be
associated with increased incidence of adverse effects
such as hypotension [27]. Intriguingly however, emer-
ging data among patients with CIDP has also demon-
strated significant correlations between dimeric IgG
level post-treatment and clinical improvement [28].
Although their clinical utility in routine practice is yet
to be established, other emerging immunoglobulin-spe-
cific biomarkers include level of sialylated IgG and the
ratio of sialylated/agalactosylated IgG-Fc levels. These
relate to the percentage of carbohydrate (galactose or si-
alic acid) binding to the immunoglobulin Fc region, the
primary site involved in both complement activation and
antibody-dependent cell-mediated cytotoxicity [29]. Pa-
tients with CIDP have been shown to have lower serum
levels of baseline sialylated IgG and sialylated/agalactosy-
lated IgG-Fc ratios. Furthermore, these biomarkers appear
to correlate with pre-treatment disease severity and in-
crease following administration of IVIg [30].
Many individuals with CIDP require long term main-
tenance treatment with IVIg to effect disease stability
and studies of serum IgG levels in treatment responders
have revealed that patients actually achieve a steady state
wherein both pre- and post-treatment IgG levels are
almost identical [23]. The implications of this are pro-
found, as it suggests there is an individual threshold
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above which patients remain stable [16]. Although at the
present time identifying this threshold in any given
patient is a matter of trial and error, further validation of
reference ranges in which disease control is achieved
provides promise for a future wherein IVIg is admin-
istered with the aim to achieve pre-specified IgG
levels [23].
Electrophysiologic biomarkers
While electrophysiology has an established role in the
diagnosis of CIDP, its ability to monitor response has
not been as clearly defined. Furthermore, the degree of
nerve demyelination and axonal injury at diagnosis does
not appear to predict either response to treatment or
long-term disability [31]. From a longitudinal perspec-
tive, while serial nerve conduction studies are objective
and reproducible measures of electrophysiologic func-
tion, they appear to correlate surprisingly poorly with
clinical progression or resolution [32].
Studies involving patients with biopsy proven CIDP
demonstrated that while electrophysiologic changes were
present in all participants at diagnosis, serial nerve
conduction studies at 4, 8 and 12 months did not correl-
ate well with improvement as measured by functional
scores [33]. Despite being stable on treatment or even
experiencing clinical improvement, most patients did
not consistently show normalisation in nerve conduction
studies at 12 months, and a significant proportion actu-
ally demonstrated deterioration in motor and sensory
amplitudes likely reflecting secondary axonal loss.
The discordance between clinical status and neuro-
physiology was most apparent in motor and sensory
studies of median and ulnar nerves in the upper limb
[33]. While motor studies in the lower limb did seem to
parallel functional status better, this correlation was again
unexpectedly poor and sensory studies when obtainable
were rarely reflective of interval clinical direction.
This discrepancy can in part be attributed to the poor
relationship between sensory deficits and functional
impairment. While distal sensory deficits in patients
with CIDP often persist and occasionally worsen despite
treatment (reflecting a degree of irreversible axonal loss),
this rarely contributes to functional disability and as such
it comes as no great surprise that the correlation between
sensory studies and functional scores is poor [34].
Despite being a chronic disease, long term electro-
physiologic monitoring data in CIDP has not been
widely published. Observational studies up to 24months
after diagnosis suggest that certain electrophysiologic
parameters and in particular resolution of conduction
block may be useful in monitoring disease activity but
the clinical utility of using such selective electrophysio-
logic biomarkers is difficult to assess and unlikely to
reflect an efficient use of resources [35].
Use of a composite electrophysiologic score assessing
averaged compound motor action potential (CMAP)
amplitudes in a number of motor nerves appeared to
correlate with treatment response in post-hoc analyses of
the ICE study [36]. Further validation of this and other
composite measures such as averaged motor conduction
velocities are however required to support the use of this
innovative electrophysiologic biomarker.
The approach to patients who remain clinically stable
but who develop interval deterioration in nerve conduc-
tion studies is controversial. While observational data
has suggested that extensive axonal degeneration is a
marker of poor outcome, the role for escalating
immunotherapy in the setting of clinical stability has not
been adequately studied [2]. Although it has been
proposed that patients who develop new demyelinating
lesions while on maintenance therapy may benefit from
higher doses of IVIg to improve function and possibly pre-
vent relapse this runs the risk of significantly over-treating
patients who have remained clinically well [37].
Multiple explanations for the disparity between elec-
trophysiologic demyelination and disease activity have
been postulated to explain why evidence of new demye-
linating lesions does not always parallel clinical decline.
CIDP remains a dynamic process that involves constant
segmental demyelination and remyelination, and it is
likely this constant spectrum of nerve injury cannot be
easily assessed through electrophysiology at any single
time point. Biopsy studies revealing so-called ‘onion
bulb’ formations which represent repetitive Schwann cell
induced proliferation provides strong evidence for a
continuous regeneration routine at the microscopic level
which cannot be easily quantified with the use of nerve
conduction studies.
Imaging biomarkers
While ‘onion bulb’ formation is a pathologic biopsy find-
ing, there is evidence that quantifiable nerve root hyper-
trophy as measured by magnetic resonance imaging may
be a possible radiologic correlate and the advent of
advanced imaging techniques such as nerve ultrasound
and magnetic resonance neurography have opened the
way for multimodal assessments of nerve pathology [38].
Ultrasonography provides precise measures of nerve
anatomy in addition to information regarding fascicu-
lar related muscles and blood vessels. Use in com-
pressive neuropathies like carpal tunnel syndrome
has highlighted its high sensitivity in detecting
subclinical nerve damage even in patients without
symptoms [39]. Furthermore, the ability to identify
demyelinating neuropathies like Charcot-Marie-Tooth
disease and CIDP has been particularly promising,
with one study reporting sensitivities of up to 100
and 86% respectively [40].
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Specificity in CIDP diagnosis can be increased through
the use of ultrasound in addition to electrophysiology.
One study comparing patients with diabetic polyneurop-
athy fulfilling electrophysiologic criteria for CIDP to
those with clinically diagnosed CIDP demonstrated that
cross-sectional area as measured on ultrasound reliably
distinguished these two groups apart [41].
In addition to being a useful adjunct in diagnosis,
longitudinal changes in nerve ultrasound characteristics
appear to correlate well with clinical status and
amelioration of nerve enlargement during treatment
with IVIg concordant with clinical improvement may
thus be a promising surrogate biomarker of disease
stability [42].
There are however several technical factors that can
limit ultrasound use. In particular, meaningful sono-
graphic evaluation of the nervous system is only possible
at accessible sites in the distal extremities and its ability
to accurately visualise proximal structures like the
lumbosacral plexus and spinal nerves is extremely
limited. This is particularly pertinent in conditions like
CIDP, as electrophysiologic markers at disease onset (de-
layed F-waves and absent H-responses) strongly suggest
the process begins as a proximal polyradiculopathy that
only subsequently extends distally.
Using magnetic resonance imaging, it is possible to
assess these proximal areas and thus identify structural
evidence of peripheral nerve pathology. Early MRI stud-
ies involving gadolinium enhanced T1-weighted se-
quences described enhancement of the cauda equina (in
up to 70% of cases) and less commonly nerve root
enlargement however concluded that these features
could not correlate with either clinical signs or disease
severity [43]. Modern sequences for MR-neurography
however, which include a combination of fat-suppressed
T2- and T1-weighted sequences can reliably quantify
cross-sectional nerve area and demonstrate nerve signal
change, thus providing objective measures of disease
activity that can be monitored over time.
As assessed by MR neurography, patients with
CIDP had significantly enlarged cross-sectional areas
and signal intensity in nerves of the lumbosacral
plexus, the sciatic nerve at the level of the thigh and
major nerves of the upper limb when compared with
normal controls and this suggests it can be used as a
highly specific diagnostic aid [44]. While correlations
of cross-sectional area and T2 signal intensity with
clinical severity failed to reach significance, imaging
parameters correlated strongly with neurophysiology
markers of nerve injury, in particular lower limb
CMAP amplitude and F-wave latency. Consequently,
although multiparametric MRI imaging can be used
as a highly specific diagnostic tool, its role in estimat-
ing severity is yet to be fully elucidated [45].
In addition to examining nerve pathology, adjunctive
myopathic imaging in patients with CIDP may help
assess disease severity, with structural alterations in
muscle tissue composition as a consequence of denerv-
ation also correlating closely with clinical weakness [46].
Several studies have demonstrated that thigh muscles of
patients with CIDP showed a significantly elevated intra-
muscular fat fraction compared with controls [45, 46].
While both nerve signal change and structural nerve
or muscle measurements provide valuable diagnostic
data and indirect estimations of disease activity the
emerging use of advanced functional MRI techniques
involving diffusion tensor imaging (DTI) promises to
yield additional quantitative information which can be
used to monitor disease activity in CIDP. By using diffu-
sion sensitizing-gradients to measure proton diffusion
within individual voxels DTI allows visualization of
nerve fibre tracks and recent studies have shown prom-
ise in its ability to provide quantitative data on myelin
sheath integrity [45–47].
Genomics in CIDP: A novel biomarker?
Clinical genomics is starting to play an increasingly
important role in our understanding of disease patho-
genesis and has offered the potential for an increased
application of high-precision medicine in a variety of
autoimmune conditions.
Differential gene expression in CIDP as measured
through micro-array based analysis of human sural nerve
biopsies has provided information on a number of
up-regulated genes in these patients [48]. As sural nerve
biopsies are rarely performed due to their invasive nature
and the potential for permanent complications, subse-
quent investigations were carried out to see if these upreg-
ulated genes could also be identified in skin biopsies.
One study suggested that five genes were reliably up-
regulated in skin biopsy samples in CIDP patients, with
the Allograft Inflammatory Factor-1 gene most signifi-
cantly associated. While it remains unclear what triggers
this upregulation, all these genes have been implicated
in the immune cascade [49]. Unfortunately, while signifi-
cant differences in gene expression have been identified
in CIDP patients compared to normal controls, these
genes also appear to be upregulated in other conditions
like vasculitis and even diabetic neuropathy and thus
more specific genetic biomarkers in CIDP are required.
There are early indications that genetic profiling may
open novel monitoring strategies during treatment with
IVIg. Pilot data involving patients treated with immuno-
globulin demonstrated that IVIg drove the down-regula-
tion of a number of genes involved in the systemic
inflammatory response however these findings need to
be validated in larger populations until more definitive
conclusions can be drawn [50].
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Predicting response to IVIG withdrawal
Current criteria for immunoglobulin use mandate con-
sidering cessation of IVIg in all patients after 12 months
of treatment. Discontinuing immunoglobulin therapy
can however be associated with recrudescence of a
significant symptom burden, and relapse rates of up to
45% at 6 months have been reported [51]. Of particular
concern, the re-introduction of IVIg as rescue therapy in
relapsed patients may not always lead to full recovery
although the reasons for this are not well elucidated
[52]. Consequently, just as reliable biomarkers are neces-
sary to monitor disease activity on IVIg, so too is it
crucial to develop the ability to predict response to im-
munoglobulin withdrawal.
Observational data of clinical characteristics in pa-
tients with CIDP revealed no significant difference in
topography of weakness (proximal vs. distal), type of
neuropathic disturbance (sensory vs motor) or pre-treat-
ment severity between individuals who could be weaned
from therapy and those who were treatment dependent
[32]. This strongly suggests that using clinical phenotype
alone is a poor predictor of response to treatment
cessation.
While serum-based and imaging biomarkers have
shown promise in being able to quantify disease activity,
their role in predicting response to a discontinuation of
therapy has not been determined (see Table 2). Conversely,
despite some discordance between neurophysiology and
predicting clinical outcome, certain electrophysiologic
parameters have been shown to be useful in identifying
patients at high risk of an inflammatory relapse following
withdrawal of treatment.
Standard markers of demyelination on nerve conduction
studies include slowing of nerve conduction velocity, tem-
poral dispersion, prolongation of distal motor and F-wave
latencies in addition to conduction block. Due to the fact
that CIDP is a dynamic disease process that involves per-
petual demyelination and remyelination these electro-
physiological biomarkers do not necessarily correlate well
with functional based clinical scores at individual time
points. Nonetheless, use of these markers in stratifying
risk of relapse can help influence decision-making by
predicting patients who may be good candidates for wean-
ing therapy.
An ICE extension study which randomised treatment
responders into either continued IVIg or placebo (i.e.
Table 2 Emerging biomarkers in CIDP
Investigation Comments
Serum biomarkers
Paranodal antibodies anti-NF155 IgM Can be seen in GBS, CMT and CIDP
anti-NF155 IgG4 Highly specific for CIDP, often characterised by younger age




Serologic response to IVIg Change in total IgG level
IgG dimer index
Level of sialylated IgG
Electrophysiology
Resolution of conduction block Correlate well with longitudinal disease activity unlike most
other nerve conduction studies
Averaged CMAP amplitude
Accumulation of demyelinating features Predictor of relapse following treatment withdrawal
Imaging
High resolution ultrasound Cross sectional nerve area
Nerve echogenicity Role still unclear
Nerve vascularization
Magnetic resonance neurography Cross sectional nerve area
Nerve signal change
Functional MRI (Diffusion tensor imaging) Fractional anisotropy Correlate well with electrophysiological markers of demyelination
Radial diffusivity Role still unclear
Axial diffusivity
Abbreviations: NF Neurofascin, GBS Guillain Barre Syndrome, CIDP Chronic inflammatory demyelinating polyneuropathy, IVIg intravenous immunoglobulin, CMAP
compound motor action potential, MRI: magnetic resonance imaging
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IVIg discontinued) performed a post-hoc analysis of
demyelinating changes in patients who subsequently
relapsed with electrophysiologic data obtained at the ini-
tial commencement of IVIg and just prior to discontinu-
ing treatment [53].
Although limited by small sample size the results ob-
tained in each group at these two time-points were
highly suggestive. All patients who relapsed demon-
strated evidence of new demyelinating features between
the two studies thus indicating that the accumulation of
an electrophysiologic burden of disease may predict
treatment dependency. Interestingly, 60% of patients in
the No-Relapse group also accumulated demyelinating
features, which suggests that number of new lesions in
itself is not a particularly specific finding. Comparing the
actual type of interval demyelinating change between the
two groups however suggested that F-wave latency and
distal compound motor action potential duration, which
had odds ratios of 14.40 and 21.00 respectively, may be
more potent biomarkers for predicting relapse following
treatment withdrawal [53].
Conclusion
The search for reliable biomarkers of disease activity in
CIDP continues. While the discovery of specific paranodal
antibodies which conform to phenotypic presentations of
disease and predict response to immunomodulation rep-
resents a major advance in our approach to individualised
treatment strategies, more ubiquitous biomarkers that
provide robust longitudinal measures of neuropathic
injury are clearly required.
Immunoglobulin treatment dependence has significant
physical and psychological consequences on patients in
addition to profound financial implications at a popula-
tion level, due to both inherent costs of treatment
administration but also downstream effects driven by
long-term patient disability.
Promising genomic studies, serum-based assays, elec-
trophysiological techniques and imaging modalities are
emerging at a rate commensurate with our greater
understanding of CIDP pathogenesis. How effectively
the use of these various complementary investigations
translates into a practical multimodal approach that has
the ability to predict an individual’s response to immuno-
globulin treatment however still remains to be seen.
Abbreviations
ΔIgG: Change in immunoglobulin G; CIDP: Chronic inflammatory
demyelinating polyneuropathy; CNTN1: Contactin-1; DTI: Diffusion tensor
imaging; Fc receptor: Fragment crystallizable receptor; GBS: Guillain
Barré Syndrome; ICE: Intravenous immunoglobulin CIDP efficacy trial;
IgG: Immunoglobulin G; INCAT: Inflammatory Neuropathy Cause and
Treatment; IVIg: Intravenous immunoglobulin; MRC: Medical Research
Council; MRI: Magnetic resonance imaging; MR-neurography: Magnetic
resonance neurography; NF155: Neurofascin-155; ONLS: Overall neuropathy
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